Swapping the TLR4 agonist for a TLR2 one yields a gentler QS-21 adjuvant
- BQS01 is a liposomal adjuvant that keeps QS-21 but replaces the TLR4 agonist MPL of AS01-type formulations with a synthetic TLR2 agonist.
- It showed a TLR2-like gene signature, stronger dendritic cell activation and T-cell priming, and higher IL-10.
- In mouse ovalbumin and varicella-zoster models, antibodies matched an MPL/QS-21 comparator with durable T-cell responses, but weight loss, local inflammation and TNF-α were lower.
💡 Points Based on the abstract
Great tractability story: a synthetic TLR2 agonist is far easier to make and QC than MPL, which is a heterogeneous lipid A mixture. The IL-10 bump probably explains the lower TNF-α; the open question is whether it also blunts durability. And how does BXY-14 compare to Pam2/Pam3-type lipopeptide chemotypes?